近日,诺华眼科撤出中国的流言再起,9月29日,有业内人士告诉健识局,基本已经确定由康哲药业接手诺华眼底疾病产品,目前一线城市康哲药业的医药代表已经开始拜访诺华雷珠单抗、布西珠单抗两款产品的客户了。今年7月,业内就开始流传,诺华眼表疾病产品已基本确定剥离,将由上药接手;两个重磅眼底疾病产品也在找下家,主要是日本参天和本土的康哲药业两家企业在竞争。雷珠单抗是全球第一款用于眼底病变的VEGF药物,...
Source Link近日,诺华眼科撤出中国的流言再起,9月29日,有业内人士告诉健识局,基本已经确定由康哲药业接手诺华眼底疾病产品,目前一线城市康哲药业的医药代表已经开始拜访诺华雷珠单抗、布西珠单抗两款产品的客户了。今年7月,业内就开始流传,诺华眼表疾病产品已基本确定剥离,将由上药接手;两个重磅眼底疾病产品也在找下家,主要是日本参天和本土的康哲药业两家企业在竞争。雷珠单抗是全球第一款用于眼底病变的VEGF药物,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.